Live Breaking News & Updates on Carman Giacomantonio

Stay updated with breaking news from Carman giacomantonio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent

Sona Nanotech Inc. is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC to be the Company s Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical. ....

New Brunswick , David Regan , Company Stock Option Plan , Health Canada , Dalhousie University , Nova Scotia Newsfile Corp , Company Option Plan , Professor Of Surgery At Dalhousie University , Health Sciences Centre , Sona Nanotech Inc , Company Or Sona , Carman Giacomantonio , Chief Medical , Surgical Oncologist , Sciences Centre , Advisory Board , Principal Investigator , Targeted Hyperthermia Therapy , Stock Option Plan , Multilateral Instrument , Minority Security Holders , Special Transactions , Targeted Hyperthermia ,

Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model

Sona Nanotech Inc. announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University which confirms that the previously. ....

United States , New Brunswick , David Regan , Carman Giacomantonio , Sona Nanotech Inc , Dalhousie University The Study , Health Canada , Drug Administration , Company Or Sona , Nova Scotia Newsfile Corp , Dalhousie University , Principal Investigator , Sona Advisory Board , Targeted Hyperthermia , Targeted Hyperthermia Therapy ,

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New Brunswick , United States , Carman Giacomantonio , Giacomantonio Immuno , David Regan , Company Or Sona , Health Canada , Nova Scotia Newsfile Corp , Drug Administration , Sona Nanotech Inc , Giacomantonio Immuno Oncology Research Group , Dalhousie University , Principal Investigator , Sona Advisory Board , Study Interim Results , Triple Negative Breast Cancer Mouse Model , Targeted Hyperthermia Therapy ,

Sona Nanotech Inc.: Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Sona Nanotech Inc.: Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , New Brunswick , Carman Giacomantonio , Dennis Riedl , Giacomantonio Immuno , David Regan , Health Canada , Company Or Sona , Nova Scotia Newsfile Corp , Drug Administration , Sona Nanotech Inc , Giacomantonio Immuno Oncology Research Group , Dalhousie University , Principal Investigator , Sona Advisory Board , Study Interim Results , Triple Negative Breast Cancer Mouse Model , Targeted Hyperthermia , Targeted Hyperthermia Therapy , Sona Nanotech ,

Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Sona Nanotech Inc. announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University . An update received by the Company indicates. ....

New Brunswick , David Regan , Giacomantonio Immuno , Carman Giacomantonio , Health Canada , Drug Administration , Company Or Sona , Nanotechnology Characterization Laboratory , Us National Cancer Institute , Sona Nanotech Inc , National Cancer Institute , Nova Scotia Newsfile Corp , National Institute Of Standards , Giacomantonio Immuno Oncology Research Group , Dalhousie University , Targeted Hyperthermia Therapy , Principal Investigator , Targeted Hyperthermia , Cancer Institute , National Institute ,